文献速递小儿耳鼻咽喉鼻科

儿童下鼻甲减容术疗效的前瞻性分析

Efficacy of inferior turbinate reduction in pediatric patients: a prospective analysis.
PubMed 文献 · Int Forum Allergy Rhinol · 2021-06-16

本研究前瞻性评估96例18岁以下患儿下鼻甲减容术(ITR)后1年鼻塞症状与每日用药情况,伴或不伴过敏性鼻炎(AR)者均纳入。术后12个月NOSE总分中位数由65分降至20分(p<0.001),每日用药中位数由1种降至0种(p=0.017);AR患儿术后NOSE评分仍显著高于无AR者(β=11.6,95%CI 0.676-22.5,p=0.038)。结论提示慢性鼻塞尤其伴AR儿童需多模式治疗。

要点

  • 儿童ITR术后12个月NOSE评分和每日用药量均显著改善。
  • 伴AR患儿术前术后用药更多,术后12个月鼻塞评分仍更高。
  • 慢性鼻塞儿童尤其伴AR者需多模式综合治疗。

核心结论

  • 儿童下鼻甲减容术后12个月鼻塞症状和每日用药显著改善。
  • 伴过敏性鼻炎患儿术后鼻塞评分仍显著高于无过敏性鼻炎者。
  • 慢性鼻塞尤其伴过敏性鼻炎儿童需多模式治疗。

研究设计与样本

  • 前瞻性研究,纳入96例18岁以下接受下鼻甲减容术(单独或联合非鼻窦手术)的患儿。
  • 术前及术后3、6、12个月收集NOSE问卷评分,并分析每日相关药物使用数量与类型。
  • 采用Wilcoxon符号秩检验和McNemar检验分析,伴与不伴过敏性鼻炎者用Wilcoxon秩和检验比较。

主要发现

  • NOSE总分中位数从术前65分(范围0-100)降至术后12个月20分(范围0-100)(z=7.12,p<0.001)。
  • 每日药物中位数从术前1种(范围0-4)降至术后0种(范围0-5)(z=2.38,p=0.017)。
  • 术后12个月,伴过敏性鼻炎者NOSE评分仍显著高于无过敏性鼻炎者(β=11.6;95%CI 0.676-22.5;p=0.038)。

临床怎么用

  • 对药物治疗和腺样体切除后仍鼻塞的儿童,下鼻甲减容术可作为辅助手术选择。
  • 伴过敏性鼻炎患儿术后仍需关注鼻塞症状和用药,应纳入多模式管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic nasal congestion is a common presentation in the pediatric setting. For patients who fail to respond to maximal medical therapy and adenoidectomy, inferior turbinate reduction (ITR) may be a reasonable adjuvant surgical approach. Our objective was to prospectively evaluate nasal congestion symptoms and daily medication use in the year following ITR in children with and without allergic rhinitis (AR). METHODS: Patients younger than 18 years undergoing ITR alone or in combination with nonsinonasal procedures were enrolled. Scores from the Nasal Obstruction Symptom Evaluation (NOSE) survey were collected preoperatively and at 3, 6, and 12 months postoperatively from 96 patients. Number and type of pertinent daily medications utilized were also analyzed using Wilcoxon signed-rank and McNemar's tests. Patients with and without comorbid AR were then compared using Wilcoxon rank-sum tests. RESULTS: Median (range) NOSE sum scores significantly improved from preoperative median of 65 out of 100 points (0-100) to 20 (0-100), (z = 7.12, p < 0.001) at 12 months postoperatively. The median number of daily medications was significantly reduced from 1 (range, 0-4) preoperatively to 0 (range, 0-5) postoperatively (z = 2.38, p = 0.017). Fifty-six (58.3%) patients had AR. AR patients received more medications preoperatively and postoperatively compared with those without AR (z = -2.96, p = 0.003; z = -2.23, p = 0.024). At 12 months, NOSE scores remained significantly greater in patients with AR compared with those without AR (β = 11.6; 95% confidence interval [CI], 0.676-22.5; p = 0.038). CONCLUSION: Our data highlight the need for a multimodal approach to chronic nasal congestion, particularly in children with AR.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Whelan RL, Shaffer AD, Stapleton AL, et al. Efficacy of inferior turbinate reduction in pediatric patients: a prospective analysis. Int Forum Allergy Rhinol. 2021. PMID: 34132059. doi:10.1002/alr.22849

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。